Chronic inflammatory demyelinating polyradiculoneuropathy is a rare autoimmune-related condition that affects nerve signaling ...
This week, we are going to continue down the road of autoimmune peripheral nerve conditions to discuss two that we have touched on in the past—Guillain-Barré Syndrome and CIDP (chronic inflammatory ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...
But you can decrease CIDP anxiety with techniques to stay grounded when you’re dreading an appointment or the return of symptoms. The news that you have a life-changing chronic illness can feel ...
IVIg and other treatments for chronic inflammatory demyelinating polyneuropathy (CIDP) slow or stop your immune systems attack on the protective coating (myelin sheath) around your nerves. But ...
A blockbuster Argenx therapy now has an additional FDA approval as a treatment for a rare autoimmune disorder affecting nerves, marking the first new treatment for this condition in decades and a new ...
CIDP significantly affects daily life, with many patients needing mobility aids and caregiver support, impacting employment and quality of life. A real-world survey showed 22% of CIDP patients were ...
Primary endpoint met (p=0.000039); VYVGART Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse versus placebo 67% of patients in open-label Stage A demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results